RenovoRx, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by RenovoRx, Inc. on March 27, 2026, reporting events occurring as early as March 24, 2026. The Company is a Delaware corporation with its principal executive offices in Mountain View, California, and its common stock trades on the Nasdaq Capital Market under the symbol "RNXT". The filing is primarily focused on executive leadership changes and compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figures disclosed relate to executive compensation:
- Base Salary: $450,000 annualized for the Executive Chairman and Chief Medical Officer.
- Work Commitment: Minimum of 30 hours per week.
- Discretionary Bonus: Up to 40% of the annualized base salary, contingent on company and individual performance.
- Equity Compensation: Eligibility for annual grants of stock options and restricted stock units under the 2021 Omnibus Equity Incentive Plan.
Material Changes
The primary material change reported is the appointment of Ramtin Agah, M.D., to the newly created position of Executive Chairman, effective February 27, 2026. Dr. Agah continues to serve as Chief Medical Officer. This appointment was formalized by the Board on March 24, 2026, and accompanied by a new offer letter that amends and restates a prior consulting agreement dated January 1, 2018. A Change in Control and Severance Agreement dated November 10, 2025, remains in full force and effect.
Outlook, Risks, and Management Commentary
Management commentary is limited to the terms of the new executive appointment. The employment is structured as "at-will," allowing either party to terminate the relationship at any time. The filing notes that the first discretionary bonus will be payable in 2027 based on 2026 performance. No specific guidance, risks, contingencies, or unusual items regarding the Company's operational outlook are disclosed in this filing.
Key Facts for Investor Verification
- Verify the effective date of Dr. Agah's new role as Executive Chairman (February 27, 2026) versus the filing date.
- Review the attached Exhibit 10.1 (Agah Offer Letter) for omitted details regarding equity grant specifics and vesting schedules.
- Confirm the status of the existing Change in Control and Severance Agreement dated November 10, 2025.
- Note that this filing contains no financial results; investors should refer to the most recent 10-K or 10-Q for financial health metrics.